The underlying mechanism involved the NR4A1-EREG-EGFR pathway indicated that intervention with NR4A1 in utero or during the neonatal period could reduce the risk of BPD in offspring exposed to intrauterine inflammation. Here, NR4A1 is linked to bronchopulmonary dysplasia.